Strongbridge Biopharma (SBBP) Downgraded by ValuEngine

ValuEngine downgraded shares of Strongbridge Biopharma (NASDAQ:SBBP) from a sell rating to a strong sell rating in a research note issued to investors on Wednesday morning, ValuEngine reports.

SBBP has been the subject of several other research reports. Zacks Investment Research upgraded shares of Strongbridge Biopharma from a hold rating to a buy rating and set a $5.75 target price for the company in a research note on Friday, March 1st. Oppenheimer reiterated a buy rating on shares of Strongbridge Biopharma in a research note on Tuesday, March 19th. TheStreet upgraded shares of Strongbridge Biopharma from a d- rating to a c- rating in a research note on Tuesday, February 26th. BidaskClub upgraded shares of Strongbridge Biopharma from a strong sell rating to a sell rating in a research note on Friday, April 26th. Finally, Cantor Fitzgerald set a $12.00 price objective on shares of Strongbridge Biopharma and gave the company a buy rating in a research note on Tuesday, February 26th. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. Strongbridge Biopharma presently has a consensus rating of Buy and a consensus price target of $13.29.

Shares of SBBP traded down $0.19 during trading hours on Wednesday, hitting $3.47. The company’s stock had a trading volume of 562,362 shares, compared to its average volume of 182,124. The company has a market capitalization of $187.96 million, a price-to-earnings ratio of 11.19 and a beta of 0.17. Strongbridge Biopharma has a 52-week low of $3.41 and a 52-week high of $8.15.

Strongbridge Biopharma (NASDAQ:SBBP) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.09. The firm had revenue of $4.34 million during the quarter, compared to the consensus estimate of $4.69 million. Strongbridge Biopharma had a net margin of 176.69% and a return on equity of 108.51%. On average, research analysts expect that Strongbridge Biopharma will post -1.52 earnings per share for the current year.

A number of large investors have recently modified their holdings of SBBP. 683 Capital Management LLC grew its stake in Strongbridge Biopharma by 183.2% during the fourth quarter. 683 Capital Management LLC now owns 848,700 shares of the biotechnology company’s stock valued at $3,802,000 after acquiring an additional 549,000 shares in the last quarter. Prosight Management LP grew its stake in Strongbridge Biopharma by 121.3% during the fourth quarter. Prosight Management LP now owns 937,900 shares of the biotechnology company’s stock valued at $4,202,000 after acquiring an additional 514,054 shares in the last quarter. 22NW LP purchased a new position in Strongbridge Biopharma during the fourth quarter valued at approximately $1,812,000. Hudson Bay Capital Management LP grew its stake in Strongbridge Biopharma by 48.1% during the fourth quarter. Hudson Bay Capital Management LP now owns 1,000,000 shares of the biotechnology company’s stock valued at $4,480,000 after acquiring an additional 324,900 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in Strongbridge Biopharma during the third quarter valued at approximately $1,290,000. 49.09% of the stock is owned by institutional investors.

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.

See Also: What is a Reverse Stock Split?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Strongbridge Biopharma (NASDAQ:SBBP)

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.